Trials / Recruiting
RecruitingNCT06658535
A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress
Novel Oxygen Therapeutic NanO2 for Mild Respiratory Distress in Phase 1b
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- NuvOx LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
EXTEND is a dose escalation study of NanO2™ in patients with mild respiratory distress who are at risk for mechanical ventilation. The study will establish dosing guidelines for a Phase 2 study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dodecafluoropentane (0.025 mL/kg) | dodecafluoropentane (0.025 mL/kg) |
| DRUG | dodecafluoropentane (0.032 mL/kg) | dodecafluoropentane (0.032 mL/kg) |
| DRUG | dodecafluoropentane (0.050 mL/kg) | dodecafluoropentane (0.050 mL/kg) |
Timeline
- Start date
- 2025-03-13
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2024-10-26
- Last updated
- 2026-01-28
Locations
2 sites across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06658535. Inclusion in this directory is not an endorsement.